INSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency
September 21 2017 - 4:01PM
Insys Therapeutics, Inc. (NASDAQ:INSY) ("INSYS" or "the Company"),
today announced the hiring of Joe McGrath as the Company’s Senior
Director of Corporate Communications, and the retention of the
Alpha IR Group (“Alpha IR”) as its investor relations agency of
record.
McGrath joins INSYS Therapeutics after nearly 16 years in public
relations and corporate communications at Medtronic, where he
served in a succession of functional roles for the neurological and
cardiovascular divisions. In his new role at INSYS, McGrath is
responsible for directing and conducting internal and external
communications for the Company, including media relations,
reputation management, and corporate brand development. McGrath
will also support investor relations in collaboration with INSYS’s
Chief Financial Officer, Andrew Long, and President and Chief
Executive Officer, Saeed Motahari.
Alpha IR is a boutique full-service investor relations
consulting firm, whose leadership team brings over 100 years of
combined Wall Street experience. Alpha IR’s healthcare specialists
will support the enhancement of the Company’s engagement strategy
with the investment community as well as provide ongoing strategic
messaging and communications support to both internal and external
stakeholders.
“Joe is a great addition to the INSYS team, and I am confident
that his deep experience and understanding of the healthcare sector
will complement our new leadership team. His immediate focus will
be on helping INSYS to establish, develop and maintain strong and
principled relationships with our key stakeholders,” Motahari said.
“Additionally, our partnership with Alpha IR is also an important
milestone for the Company, as we seek to enhance our investor
relations effort. We greatly appreciate the support we received
from In-Site Communications throughout our transition from a
privately held company to a publicly traded company.”
About INSYS
Insys Therapeutics is a specialty pharmaceutical
company that develops and commercializes innovative drugs and novel
drug delivery systems of therapeutic molecules that improve the
quality of life of patients. Using proprietary sublingual spray
technology and capabilities to develop pharmaceutical cannabinoids,
INSYS is developing a pipeline of products intending to address
unmet medical needs and the clinical shortcomings of existing
commercial products. INSYS currently markets SUBSYS® (fentanyl
sublingual spray) and SYNDROS® (dronabinol oral solution), a
proprietary, orally administered liquid formulation of dronabinol.
INSYS is committed to developing medications for potentially
treating addiction to opioids, opioid overdose, epilepsy, and other
disease areas with a significant unmet need.
SUBSYS® and SYNDROS® are trademarks of Insys Development
Company, Inc., a subsidiary of Insys Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property
of their respective owners.
About Alpha IR GroupThe Alpha IR Group is a
premier full-service investor relations consulting firm. The firm
has unparalleled experience building best-in-class IR programs that
focus on protecting and enhancing its clients’ reputations,
credibility, and ultimately, their valuation. Alpha IR specializes
in strategic messaging, investor management and targeting, program
measurement, perception studies, IPOs, transaction and crises
services, activist counsel, and investor day events, among many
other services. The firm brings deeply rooted Wall Street
backgrounds to support a client base that spans seven industry
verticals and represents over $100 billion of equity value trading
on public exchanges in North America. Alpha IR has offices in
Chicago, New York, and Boston. For more information, please visit
www.alpha-ir.com.
CONTACT:
Media RelationsJoe McGrathSenior Director, Corporate
CommunicationsINSYS
Therapeutics480-500-3101jmcgrath@insysrx.com
Investor RelationsJackie Marcus or Chris HodgesAlpha IR
Group312-445-2870 INSY@alpha-ir.com
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024